Resubmit the New Drug Application for Libervant to the FDA
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company expects to resubmit the NDA, based on further FDA feedback, during the first half of 2021.”
What we found
Evidence strength A What the grades mean
The company successfully resubmitted the New Drug Application for Libervant to the FDA in June 2021, which falls within the first half of 2021.
-
A Aquestive Therapeutics, Inc. 10-Q filed 2021-11-02
“In June 2021, we resubmitted our New Drug Application ("NDA") to the FDA.” ✓ confirmed on the page
Market reaction: the shares moved +13.8% against the S&P 500 over the three sessions around the disclosure (1 Nov 2021 to 4 Nov 2021). What this measures
Checked 24 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Language weakened: expected → aspirational
- 2 versions
-
Version 1 · original · stated 7 Jan 2021
Deadline 30 Jun 2021 (“during the first half of 2021”) · wording expected
-
Version 2 · stated 8 Jan 2021
Deadline 30 Jun 2021 (“during the first half of 2021”) · wording aspirational
“Aquestive intends to resubmit the NDA as quickly as possible, based on further FDA feedback, during the first half of 2021”
-
Version 3 · stated 17 Sep 2026
Deadline 30 Sep 2026 (“Q3 2026”) · wording expected
“expect to resubmit in Q3 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Resubmit
- Deliverable
- Libervant NDA resubmission
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: based on further FDA feedback
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aquestive Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-AQST-021239 · Corrections policy